The QBF portfolio is diversified by finance stage and product type. Investments are made from seed to mezzanine stages, specialising in companies in which the QBF team members have extensive networks and depth of technical and market experience.

Our sector focused experience and quality networks allow us to respond quickly to deal flow opportunities.

Driven by increasing healthcare costs and demographic trends our pharmaceutical product investments are focused on therapeutically effective treatments for known diseases that fulfill unmet market needs, as well as discovery products that are capable of removing significant bottlenecks within the drug discovery pipeline.

The potential for a consumer healthcare product to attract a significant share of a growing market through it's ability to influence consumer decision making is a crucial consideration for investment.

Similarly medical devices must address a major patient population, stimulate early adoption by healthcare professionals and follow a regulatory pathway that is rapidly and realistically achievable.

Our biomaterials product focus is at the convergence of material and human bioscience, and identifies companies that have uniquely exploitable technology that can be competitively positioned into several existing and emerging markets.

QBF invests in companies that provide the best core value proposition in terms of unique and exploitable technology capable of development into several different drug, disease treatment or lifestyle products.

These emerging technologies must be synergistically matched to emerging markets or remain demonstrably appealing to the majority of customers in a sizable existing market. Well defined differentiating attributes of the product should provide an intimidating barrier to competition.

Companies led by internal champions and management teams with experience appropriate to the sector and stage of development of the products are most likely to attract QBF investment. The ideas and products in their own right should be capable of attracting superior human capital.

The optimal time for QBF to invest is dependent upon external market factors or conditions and the associated valuation.

QBF prefers to co-invest or syndicate with top tier life science venture capital specialists with pedigree track records, mid- to long-term vision and an expanding pie mentality.

QBF builds and sustains close relationships with it's portfolio companies in order to assist management with product focus and the identification of multiple pathways to commercial success.

We are continually developing relationships with key corporations that can provide strategic support for our portfolio companies.

Our major core capability is to provide access to global markets and unrivalled industry resources throughstrong ties to leading pharmaceutical, technical, financial and venture capital expertise throughout the world.

Additionally our strong fiscal position provides us with the flexibility to contribute follow-on investment through fluctuating market conditions.

Positioning for liquidity through the recognition and creation of exceptional acquisition and listing opportunities is the first step prior to investment.

Once invested we use all our resource and deep industry experience to ensure an independent and sustainable business is created prior to exit.

QBF recognises the importance of liquidity to all stakeholders.